A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma

Christopher W. Ryan, Jacqueline Vuky, Joseph S. Chan, Zunqiu Chen, Tomasz M. Beer, Deirdre Nauman

    Research output: Contribution to journalArticlepeer-review

    8 Scopus citations


    Purpose: This phase II study evaluated the activity of combined treatment with the mTOR inhibitor everolimus and the PDGFR inhibitor imatinib in patients with previously-treated, advanced renal carcinoma. The primary endpoint was estimation of the 3-month progression-free rate. Patients and methods: Eligible patients had metastatic or unresectable clear cell renal carcinoma, at least one prior systemic therapy, no prior mTOR inhibitor therapy, performance status 0-2, and measurable disease. Treatment consisted of everolimus 2.5 mg p.o. daily and imatinib 600 mg p.o. daily. The primary endpoint was the 3-month progression-free rate. Results: The study was closed after the first 19 patients because of an insufficient number of patients who were progression-free at 3 months. The 3-month progression-free rate was 49% (95% C.I. 23%, 72%) and the median progression-free survival was 2.9 months (95% C.I. 1.9, 6.2). Toxicities with an incidence of >50% included nausea, elevated serum creatinine, edema, anemia, hypocalcemia, fatigue, diarrhea, vomiting, and dyspnea, and leukopenia. Conclusion: The combination of everolimus with imatinib in previously treated patients with advanced renal carcinoma did not result in a sufficient 3-month progression-free rate to warrant further investigation of this combination.

    Original languageEnglish (US)
    Pages (from-to)374-379
    Number of pages6
    JournalInvestigational New Drugs
    Issue number2
    StatePublished - Apr 2011


    • Everolimus
    • Imatinib
    • Phase II clinical trial
    • Renal cell carcinoma

    ASJC Scopus subject areas

    • Oncology
    • Pharmacology
    • Pharmacology (medical)


    Dive into the research topics of 'A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma'. Together they form a unique fingerprint.

    Cite this